In the last week, the Pharma industry is up 2.1%, with Caliway Biopharmaceuticals up 12%. In the last 12 months, the industry was up 12%. As for the next few years, earnings are expected to grow by 42% per annum.
Has the Taiwanese Pharma Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Thu, 21 Sep 2023 | NT$549.4b | NT$101.7b | NT$9.6b | 22.2x | 57.1x | 5.4x |
Sat, 19 Aug 2023 | NT$543.8b | NT$101.7b | NT$9.6b | 21.5x | 56.5x | 5.3x |
Mon, 17 Jul 2023 | NT$569.2b | NT$98.7b | NT$10.1b | 16.9x | 56.6x | 5.8x |
Wed, 14 Jun 2023 | NT$579.4b | NT$98.6b | NT$10.1b | 17x | 57.6x | 5.9x |
Fri, 12 May 2023 | NT$563.2b | NT$92.2b | NT$8.6b | 20.1x | 65.3x | 6.1x |
Sun, 09 Apr 2023 | NT$587.2b | NT$91.2b | NT$8.5b | 21.1x | 69.1x | 6.4x |
Tue, 07 Mar 2023 | NT$565.7b | NT$85.0b | NT$7.7b | 24.1x | 73.7x | 6.7x |
Thu, 02 Feb 2023 | NT$495.4b | NT$84.6b | NT$7.9b | 20x | 62.8x | 5.9x |
Sat, 31 Dec 2022 | NT$502.1b | NT$84.6b | NT$7.9b | 21.8x | 63.7x | 5.9x |
Mon, 28 Nov 2022 | NT$476.9b | NT$84.6b | NT$7.9b | 16.3x | 60.5x | 5.6x |
Wed, 26 Oct 2022 | NT$382.0b | NT$78.9b | NT$4.3b | 16.7x | 88.3x | 4.8x |
Fri, 23 Sep 2022 | NT$456.2b | NT$78.9b | NT$4.3b | 18.3x | 105.5x | 5.8x |
Sun, 21 Aug 2022 | NT$425.3b | NT$79.0b | NT$4.3b | 18x | 97.8x | 5.4x |
Tue, 19 Jul 2022 | NT$375.6b | NT$76.8b | NT$4.4b | 21.5x | 86x | 4.9x |
Thu, 16 Jun 2022 | NT$385.2b | NT$76.8b | NT$4.4b | 21.3x | 88.2x | 5x |
Sat, 14 May 2022 | NT$367.0b | NT$76.1b | NT$6.3b | 20.2x | 58.7x | 4.8x |
Mon, 11 Apr 2022 | NT$408.2b | NT$76.4b | NT$6.8b | 20.9x | 60.4x | 5.3x |
Wed, 09 Mar 2022 | NT$385.5b | NT$76.5b | NT$8.5b | 19.5x | 45.3x | 5x |
Fri, 04 Feb 2022 | NT$379.4b | NT$76.7b | NT$8.5b | 18.9x | 44.8x | 4.9x |
Sun, 02 Jan 2022 | NT$394.6b | NT$76.7b | NT$8.5b | 18.6x | 46.6x | 5.1x |
Tue, 30 Nov 2021 | NT$381.5b | NT$76.7b | NT$8.5b | 17.8x | 45.1x | 5x |
Thu, 28 Oct 2021 | NT$373.6b | NT$76.0b | NT$10.4b | 17.2x | 35.8x | 4.9x |
Sat, 25 Sep 2021 | NT$357.1b | NT$76.0b | NT$10.7b | 18.8x | 33.3x | 4.7x |
Mon, 23 Aug 2021 | NT$342.3b | NT$76.0b | NT$10.7b | 19.7x | 31.9x | 4.5x |
Sat, 10 Jul 2021 | NT$369.1b | NT$76.0b | NT$10.7b | 19.1x | 34.4x | 4.9x |
Fri, 02 Apr 2021 | NT$363.3b | NT$74.2b | NT$12.5b | 19.4x | 29x | 4.9x |
Mon, 04 Jan 2021 | NT$343.5b | NT$72.1b | NT$8.4b | 18.5x | 40.7x | 4.8x |
Thu, 08 Oct 2020 | NT$376.4b | NT$71.7b | NT$6.5b | 18.6x | 58x | 5.2x |
58x
How does Taiwanese Pharma compare with similar industries?
TW Market | -0.29% | |
Healthcare | -0.25% | |
Pharma | -0.39% | |
Pharma | -0.39% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
6919 Caliway Biopharmaceuticals | NT$424.00 | 11.9% +NT$2.8b | n/a | PS932.6x | |
6932 Mercury Biopharmaceutical | NT$20.70 | 8.1% +NT$644.7m | n/a | PS3212.8x | |
6586 CHO Pharma | NT$82.50 | 2.5% +NT$368.0m | -54.3% | PS252991.1x | |
6677 Anxo Pharmaceutical | NT$51.20 | -2.3% NT$326.2m | 142.1% | PE85.6x | |
6785 Alar Pharmaceuticals | NT$149.50 | 3.1% +NT$256.5m | 65.6% | PS10651.9x |